| Zacks Company Profile for Advaxis, Inc. (ADXS : OTCBB) |
|
|
| |
| • Company Description |
| Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Number of Employees: 15 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.07 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 531,993 shares |
| Shares Outstanding: 145.64 (millions) |
| Market Capitalization: $9.90 (millions) |
| Beta: 2.14 |
| 52 Week High: $0.20 |
| 52 Week Low: $0.06 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-18.07% |
-10.29% |
| 12 Week |
-35.61% |
-27.63% |
| Year To Date |
-56.30% |
-46.61% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
9 DEER PARK DRIVE SUITE K-1
-
MONMOUTH JUNCTION,NJ 08852
USA |
ph: 609-452-9813
fax: 609-452-9818 |
ir@advaxis.com |
http://www.advaxis.com |
|
|
| |
| • General Corporate Information |
Officers
Kenneth Berlin - President; Chief Executive Officer and Director
David Sidransky - Chairman
James Patton - Vice Chairman
Richard Berman - Director
Samir Khleif - Director
|
|
Peer Information
Advaxis, Inc. (CORR.)
Advaxis, Inc. (RSPI)
Advaxis, Inc. (CGXP)
Advaxis, Inc. (BGEN)
Advaxis, Inc. (GTBP)
Advaxis, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 007624307
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/13/22
|
|
Share - Related Items
Shares Outstanding: 145.64
Most Recent Split Date: 3.00 (0.07:1)
Beta: 2.14
Market Capitalization: $9.90 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 06/13/22 |
|
|
|
| |
